10 Stocks Jump, Defy Market Uncertainties on Thursday

2. Soleno Therapeutics Inc. (NASDAQ:SLNO)

Soleno Therapeutics jumped by 37.61 percent on Thursday to end at $67.39 apiece as investors cheered news that it secured the approval of the Food and Drug Administration (FDA) for its diazoxide cholin—to be called Vykat XR—which aims to treat extreme hunger in patients with Prader-Willi syndrome.

The syndrome is a rare genetic disorder caused by abnormalities in chromosome 15. Its symptoms include low muscle tone, developmental delays, and behavioral challenges.

Meanwhile, extreme hunger poses a threat to people with the syndrome and can lead to severe obesity and associated health complications.

FDA’s approval followed a three-month delay after the agency classified responses from Soleno as a “major amendment” to its new drug application, requiring additional time to review.